Times shown are in EST

8:00 am Registration & Coffee

9:00 am Chair’s Opening Remarks

9:30 am Taking a Comparative Oncological Perspective to Understand the Significance of Neoantigens in Cancer Immunotherapy

  • Stanley Leon Professor Emeritus of Surgery, University of California, San Francisco School

10:00 am ImmunoID NeXT: A Comprehensive Platform for Immuno-Oncology – Improving Neoantigen Prediction, Evaluating Tumor Dynamics & Profiling Tumor Heterogeneity

  • Sean Boyle Senior Director, Bioinformatics Applications, Personalis Inc

10:30 am Targeting ERAP1 to Alter the Cancer Immunopeptidome

  • Peter Joyce Chief Executive Officer, Co-Founder , Grey Wolf Therapeutics

11:00 am An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens

  • Trevor Clancy Chief Scientific Officer & Co-Founder, OncoImmunity

11:30 am Speed Networking

12:00 pm Morning Refreshments




Evaluating Current Neoantigen Identification & Prediction Approaches to Reveal Lessons Learned from Pre-clinical Studies

12.30 Improving MHC-Associated Peptide Sequencing Approaches for Tumor Antigen Identification

• Antibody choice for immunoprecipitation of MHC from different cells and tissues can be used to target specific MHC alleles or maximize peptide output

• Optimization of HLA expression in null cell lines drives maximal presentation of target peptides or endogenous peptides for generation of teaching sets

• Immunopeptidome profiling of MHC may help to better understand how tumors interact with the immune system

Julie Rumble, Cayman Chemical, Manager, Immunology Contract Services

Maximizing Immunogenicity to Drive Clinical Development & Success

12.30 Driving the Patient’s Immune Response to Neoantigens – Vaccine Plus…What?

• Neoantigen-based vaccines are an appealing therapeutic concept, particularly for early-stage disease

• A potent immune response is key to therapeutic benefit

• Multiple immune modulators can be deployed in conjunction with vaccines to drive the magnitude of the immune response – these will be discussed

Andrew Allen, CEO, Gritstone Oncology

Navigating Through Complex Manufacturing Challenges to Reduce Process & Release Times

12.30 The Development of Personalised Autologous Clonal Neoantigen T cell therapy for the Treatment of Solid Cancer using the VELOSTM Manufacturing Platform Generates Highly Potent & Reactive CD8+ & CD4+ T Cells for Clinical Use

• Developing T cell therapies that target multiple clonal neoantigens represents a unique personalised approach to treating solid cancer

• Access to sequencing data from over 600 NSCLC patients enrolled in the UK TRACERx study has enabled the development of the Achilles PELEUSTM bioinformatic platform

• By opening an ethically approved tissue collection study NCT03517917, enabling access to matched tumour and blood samples from patients with selected cancers, our clonal neoantigen reactive T cell (cNeT) manufacturing process and supply chain has been validated for use in clinical trials

Edward Samuel, SVP Manufacturing, Achilles Therapeutics

13.00 Prediction & Identification of both HLA Class I & Class II Neo-Epitopes

• Quality of T cells are more important than quantity of T cells in the TME

• Tumour mutation burdens do not correlate with PDAC survival, but neoepitope scores, particularly a score system weighing overlapped HLA Class I and Class II epitopes, may correlate better with PDAC survival

• Both HLA Class I and Class II epitope peptides were eluted from PDAC tumour tissue by using anti-pan HLA Class I antibody and anti-pan HLA Class II antibody, respectively, followed by mass spectrometry analysis. Approximately 20% eluted

• HLA Class I epitopes and Class II epitopes are overlapped

• We propose a strategy of developing neoepitope based vaccine or T cell therapy by selecting HLA Class I and HLA Class II overlapped epitopes

Lei Zheng, Professor, John Hopkins School of Medicine

13.00 Identifying an Individual’s Relevant Immune Responses Leads to Broad Neoantigen Based Immunity via Vaccine & Cell Therapy.

• The ATLAS Bioassay identifies neoantigens by selecting targets that have generated pre-existing immunity, assuring antigen expression and recognition

• The discovery of Inhibigens™ allows the exclusion of novel inhibitory peptides that can suppress immune responses and allow accelerated tumor growth

• With 99% of selected neoantigens generating broad immunity, ATLAS selected targets can establish a comprehensive immune therapy

Thomas Davis, Chief Medical Officer, Genocea

13.00 Determining the Clinical Impact of the Logistical Challenges in Manufacturing Personalized Neoantigen Vaccines

• Minimizing manufacturing time to reduce the needle to needle time

• Reviewing the delay between antigen identification and vaccination

• Managing patient compliance during the waiting period for the personalized investigational drug

Heinz Lubenau, CEO, VAXIMM

13:30 pm Lunch & Networking




Using Novel Discovery Processes to Optimize Identification & Prediction of Effective Neoantigens

14.30 Personalized Cancer vaccines: Defining Effective Tumor T cell responses

• Update on current personalized cancer vaccine clinical approach, successes and challenges

• Improving neoantigens prediction algorithms

• Lessons learned from preclinical models

Lelia Delamare, Senior Scientist - Cancer Immunology, Genentech

Utilizing Different Delivery Platforms to Enhance Clinical Translation of Cancer Vaccines

14.30 FlowVax: A Synthetic, Adjuvanted Microsphere Peptide Vaccine Platform

• FlowVax is designed to avoid the competition of neoantigens in antigen presenting cells using size exclusion with proprietary microspheres

• Microspheres are manufactured using a scalable system to produce a dry powder that is room temperature stable

• Data will be presented from animal models as well as a breast cancer study

Scott Burkholz, Bioinformatics Scientist, Flow Pharma

Navigating Through Complex Manufacturing Challenges to Reduce Process & Release Times

14.30 Leveraging Advancements in Technology to Achieve Faster Batch Release

• What is the time to administration?

• How can we shorten the manufacturing timeline?

Niranjan Sardesai, Co-Founder, President & CEO, Geneos Therapeutics

15.00 Using Predictive Bioinformatics Algorithms to Determine Neoantigen Peptide Synthesis Difficulty & Subsequent Production Methodology

• NeoAntigen peptides have been widely reported to be difficult to synthesize due to their hydrophobicity, length, and charge

• Leveraging extensive peptide synthesis experience GenScript has developed NeoPreTM, a predictive algorithm which is able to determine peptide synthesis difficulty based on sequence alone

• NeoPreTM can then recommend the most efficient approach to successfully synthesizing peptides using one of GenScript’s many synthesis platforms

• This presentation will highlight how NeoPreTM identifies synthesis difficulty and review successful cases of difficult neoantigen peptide synthesis from several researchers

Raymond Miller, Senior Global Product Manager, Therapeutic Materials, GenScript Biotech Corporation

15.00 Adaptation of a Clinical, Orally Delivered, Therapeutic Vaccine Platform Based on Attenuated Salmonella for Neoantigen Vaccine Applications

• A genetic vaccine platform is well suited for neoantigen vaccine applications

• Ability to raise immune responses and induce clinical responses differentiates this vaccine platform from others

• The relevance of the unique mechanism of action for this vaccine platform will be discussed

Marc Mansour, CSO, Vaximm GmbH

15.00 CMC Challenges for Patient-Specific Products, It’s All in the Details

• What is needed to reduce overall process and release times?

• How to reduce your cost of goods

• Can we learn from other disease areas to improve?

Willem-Jan Krebber, COO, ISA Therapeutics B.V.

15:30 pm Afternoon Refreshments & Poster Session




16.30 Using AI To Accelerate Immunotherapy In Cancer

• Exploring our bioinformatics approaches and how we are harnessing PIONEER in developing neoantigen based therapeutics

• Leveraging AI driven prediction tools and identifying challenges in using AI technology to drive neoantigen clinical therapy

• Uncovering the right data with the right quantity and the right quality to train your algorithms to predict immunogenicity

• Pushing for fairness in technology comparisons: assessing advantages and disadvantages across current methodologies for assay technologies

Jens Kringelum, Director, Genomic Immuno-Oncology, Exaxion Biotech

16.30 Vaccibody’s APC Targeted Vaccine for Neoantigens; Update from the Clinical Study & Correlates With Clinical Responses

• Inducing a unique CD8-dominated T cell response by targeting antigens to chemokine receptors

• Clinical updates on the phase I/IIa VB N-01 trial in multiple indications parameters important for antitumour efficacy

Agnete Fredfiksen, Co-Founder, President & CSO, Vaccibody AS

16.30 Panel Discussion: Comparison of the Different Delivery Platforms

• Advantages and disadvantages of vaccines based on DNA, RNA or Protein

• Which delivery approach is the right one to use?

• What is going to be the most potent approach?

Niranjan Sardesai, Co-Founder, President & CEO, Geneos Therapeutics

Heinz Lubenau, CEO, VAXIMM

17.00 Engineered T cells for the tTreatment of Malignancy

• Challenges with current therapeutic modalities, and why engineered T cell therapeutics are an attractive option

• Challenges and improvements to in silico based prediction methods for selecting epitopes for generating TCRs against

• Current strategy for selecting epitopes for engineering T cells against using a combination of biochemical and mass spectrometric approaches

Jennie Lill, Senior Director of Proteomics & NGS, Genentech

17.00 An Update on Neoantigen Vaccination for Glioblastoma

• Background on initial GBM neoantigen vaccine trial to be provided

• Schema and rationale for follow-up study to be presented

• Ongoing and planned updates to neoantigen vaccine approach to be discussed

David Reardon, MD – Clinical Director, Center for NeuroOncology, Dana-Farber Cancer Institute

17:30 Chair’s Closing Remarks